Aggregation System Improves Analysis of Sub-Visible Particles
Aggregation System Improves Analysis of Sub-Visible Particles
Shimadzu introduces the Aggregates Sizer Aggregation Analysis System, which provides real-time quantitative evaluation of 100 nm to 10 μm sub-visible particle (SVP) aggregates. By screening and identifying aggregation-prone proteins in early-stage drug development, manufacturers can save time and reduce costs.
The Aggregates Sizer is capable of identifying all ranges of SVP particles from invisible to visible, in a single measurement in micro-sample quantities as small as 0.4 mL. It also enables quantitative evaluation of the concentration of those aggregates.
In addition, the Aggregates Sizer can execute ongoing measurements in intervals as short as one second, allowing users to evaluate rates of change at intermediate stages during the manufacturing process. A batch cell (5 mL sample capacity) enables observation of aggregation processes as samples are mechanically stimulated. This helps prevent the formation of aggregates during drug manufacturing and improves testing without the need for additional equipment.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Mechanistic Hypothesis of Toxicity: Driving Decision Making in Preclinical Translation
July 16th 2025Mechanistic toxicity hypothesis is essential in guiding decision-making and predicting toxicities during the preclinical stages of drug development. The authors highlight the growing importance of integrating advanced technologies like mass spectrometry imaging into toxicology to enhance preclinical translation, foster innovation in therapeutic development, and ultimately improve drug safety and efficacy.
